Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety, PK, and PD study of HisproUK alone and after tPA in healthy volunteers
NL-OMON45609Phase 1Active, not recruiting
- Sponsor
- Thrombolytic Science International
- Start
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of mutant pro-urokinase and tissue-plasminogen activator in thrombosis (4 arms), sponsored by Thrombolytic Science International. Primary endpoints: Maximum degree of fibrinogen degradation, Maximum degree of plasminogen consumption and 4 more. Started Mar 2017; status: active, not recruiting.
02
Drugs
mutant pro-urokinasetissue-plasminogen activator
03
Conditions
thrombosis
Beyond the preview
Go deeper on NL-OMON45609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45609.